The Global Tacrolimus Market Is Expected To Grow Significantly, Driven By the Increasing Incidence of Organ Transplantation

 

Tacrolimus Market

Tacrolimus Market, by Product Type (Tacrolimus Capsules and Tablets, Tacrolimus Ointment, Tacrolimus Injection, and Tacrolimus Granules), by Application (Immunosuppression, Dermatitis, and Others), by End User (Organ Transplant Centers, Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030.

Market Overview:

Tacrolimus is an immunosuppressive drug that is used to prevent organ rejection in individuals who have received a kidney, liver, or heart transplant. It works by suppressing the immune system, which helps to prevent the body from rejecting the transplanted organ.

Tacrolimus belongs to a class of drugs called calcineurin inhibitors. It is available in various dosage forms, including capsules, ointments, and injections. The drug is usually taken orally, and the dosage is adjusted based on the patient's age, weight, and medical condition.

In addition to its use in transplant patients, tacrolimus is also used in the treatment of certain autoimmune diseases such as eczema and psoriasis. When used as a topical ointment, tacrolimus can help to reduce inflammation and itching associated with these skin conditions.

Competitive Landscape:

Major players operating in the global Tacrolimus Market include Vibcare Pharma Pvt. Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Senju Pharmaceutical Co. Ltd., Abbott, Pfizer Inc., Dr. Reddy's Laboratories Ltd., Astellas Pharma Inc., Mylan N.V., and Novartis AG.

Key Market Drivers:

The rising prevalence of chronic diseases such as diabetes and kidney diseases has led to an increase in the number of organ transplant procedures, which is expected to augment the growth of the global tacrolimus market.  For instance, according to the Global Observatory on Donation and Transplantation, around 129,681 organ transplants were performed globally in 2020. Topical tacrolimus ointments are widely used in the treatment of skin diseases such as eczema and psoriasis, driving the demand for tacrolimus.

The increasing healthcare spending and improving healthcare infrastructure in emerging markets such as China and India are estimated to enhance the growth of the global Tacrolimus Market.

Covid-19 Impact Analysis:

The COVID-19 pandemic has also led to an increase in demand in the global tacrolimus market. Tacrolimus has been used as an immunosuppressant in COVID-19 patients to prevent cytokine storms and improve clinical outcomes. For instance, in October 2020, Aequus Pharmaceuticals Inc. extended its promotional service agreement with Sandoz Canada Inc. for the immediate release of Tacrolimus.

Key Takeaways:

·       North America is expected to dominate the global tacrolimus market, owing to the high prevalence of chronic diseases and the increasing number of organ transplant procedures in the region. For instance, according to the Health Resources and Services Administration, in 2021, over 40,000 transplants were performed in the United States. The region is also home to major players in the tacrolimus market, driving the growth of the global tacrolimus market.

·       Asia-Pacific is estimated to witness significant growth in the global Tacrolimus Market, driven by increasing healthcare spending, improving healthcare infrastructure, and the rising prevalence of chronic diseases in the region. China and India are the major contributors to the growth of the market in the region. For instance, in November 2020, Lupin Limited introduced Tacrolimus Capsules (5 mg, 1 mg, and 0.5 mg).